F-1/A: Akanda Corp. Announces Proposed Public Offering to Raise $1.5 Million

Akanda Corp. plans to offer 1,271,186 common shares and pre-funded warrants to generate gross proceeds of $1.5 million for general corporate purposes.

Summary

• Akanda Corp. has filed an amendment to its Form F-1 registration statement for a proposed public offering.
• The offering includes 1,271,186 common shares at an assumed price of $1.18 per share, aiming to raise $1,500,000 in gross proceeds.
• Pre-funded warrants are also being offered in lieu of common shares, exercisable at $0.0001 per share, for investors exceeding ownership thresholds.
• The company intends to use the net proceeds for capital expenditures, operating capacity, working capital, general corporate purposes, debt refinancing, and potential acquisitions.
• Akanda's common shares are currently quoted on the Nasdaq Capital Market under the symbol AKAN.
• The company is organized under the laws of the Province of Ontario, Canada and is an emerging growth company and a foreign private issuer as defined under applicable United States federal securities laws, and are eligible for reduced public company reporting requirements.

Sentiment

Score: 4

Explanation: The document is largely factual, but the need for capital raising and the risks involved suggest a cautious outlook. The company's financial situation creates doubt as to whether it will continue as a going concern.

Positives

• The offering will provide Akanda with additional capital for its strategic initiatives.
• The company has flexibility in allocating the net proceeds to various areas of its business.
• Akanda's status as an emerging growth company and foreign private issuer provides certain regulatory advantages.

Negatives

• Investing in Akanda's securities is highly speculative and involves a high degree of risk.
• The company has a limited operating history and minimal revenues to date.
• The company's financial situation creates doubt as to whether it will continue as a going concern.
• The company may become involved in litigation matters that are expensive and time consuming, and, if resolved adversely, could harm our reputation, business, financial condition or results of operations.
• The company will need to raise additional funding, which may not be available on acceptable terms, or at all.
• If you purchase our securities in this offering, you will incur immediate and substantial dilution in the book value of your investment.
• There is no public market for the pre-funded warrants being offered in this offering.
• We may not be able to maintain a listing of our Common Shares on Nasdaq.

Risks

• The company's limited operating history and minimal revenues pose a risk to its financial stability.
• Changes in cannabis laws, regulations, and guidelines could impact the company's operations.
• Increased competition in the cannabis industry could affect Akanda's market share and profitability.
• The company's ability to maintain its Nasdaq listing is subject to meeting certain financial requirements.
• The company's ability to raise capital and the availability of future financing is uncertain.
• The company is subject to the risks inherent in an agricultural business.
• The company is subject to the risks related to our international operations in Europe.
• The company is subject to the risks related to our regulatory framework.

Future Outlook

The company anticipates undertaking activities in the next 12 to 36 months to further grow Canmart and the BC Farms business, including securing sales to patients in the UK and obtaining licenses for THC, CBD, and hemp cultivation at the BC farm.

Industry Context

The announcement relates to the international medical cannabis market, which is estimated to be worth approximately $66.7 billion by 2032. The company is positioning itself to address the growing demand for medical cannabis-based products, particularly in the United Kingdom.

Comparison to Industry Standards

• The document mentions competitors in the UK market such as The Lyphe Group, Grow Pharma, and IPS Pharma.
• The document mentions competitors in the Canadian market such as Aurora Cannabis, Canopy Growth, Aphria, CannTrust Holdings, and Aleafia Health.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• The company's ability to execute its business plan and generate returns for investors depends on the successful deployment of the net proceeds.

Next Steps

• The company will negotiate the final public offering price with the underwriters.
• The underwriter expects to deliver the securities to purchasers in the offering on or about , 2024, subject to customary closing conditions.
• The company will use the net proceeds from this offering for capital expenditures, operating capacity, working capital, general corporate purposes and the refinancing or repayment of existing indebtedness and acquisitions of complementary products, technologies or businesses.

Key Dates

Keywords

Akanda Corp, public offering, common shares, pre-funded warrants, cannabis, medical cannabis, capital raise, AKAN, Nasdaq, securities